Cognition and depression: The effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered

Human Psychopharmacology

Volumn 25, Issue 3, 2010, Pages 193-200

  Hindmarch, Ian ^a   Hashimoto, Kenji ^b  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

Cognition; Depression; Fluvoxamine; Neurogenesis; Sigma 1 receptor

Indexed keywords

1 (3,4 DIMETHOXYPHENETHYL) 4 (3 PHENYLPROPYL)PIPERAZINE; 2 [4 METHOXY 3 (2 PHENYLETHOXY)PHENYL] N,N DIPROPYLETHYLAMINE; ANTIDEPRESSANT AGENT; FLUVOXAMINE; NERVE GROWTH FACTOR; PAROXETINE; SERTRALINE; SIGMA 1 OPIATE RECEPTOR; SIGMA OPIATE RECEPTOR; SIGMA-1 RECEPTOR;

AGGRESSION; ALZHEIMER DISEASE; AMNESIA; AMYGDALOID NUCLEUS; ANTICHOLINERGIC EFFECT; ANXIETY; ANXIETY DISORDER; BEHAVIOR CHANGE; BINDING AFFINITY; BIPOLAR DISORDER; BRAIN ATROPHY; BRAIN SIZE; CALCIUM MOBILIZATION; CELL MEMBRANE; CEREBELLUM; CHRONIC STRESS; CINGULATE GYRUS; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONCENTRATION LOSS; CONFUSION; DECISION MAKING; DEPRESSION; DISEASE ASSOCIATION; DOSE RESPONSE; ENDOPLASMIC RETICULUM; EPILEPSY; FEAR; GRAY MATTER; HEAD INJURY; HIPPOCAMPUS; HUMAN; INCIDENCE; INTELLIGENCE QUOTIENT; LEARNING DISORDER; MAJOR DEPRESSION; MITOCHONDRION; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROANATOMY; NEUROCHEMISTRY; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSESSIVE COMPULSIVE DISORDER; POSITRON EMISSION TOMOGRAPHY; POSTTRAUMATIC STRESS DISORDER; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROBLEM SOLVING; PSYCHOMOTOR RETARDATION; PSYCHOSIS; PUTAMEN; REMISSION; REVIEW; SCHIZOPHRENIA; SINGLE DRUG DOSE; STRESS; SUICIDE; TEMPORAL CORTEX; TREATMENT OUTCOME; AGONISTS; ANIMAL; COGNITION DISORDERS; DEPRESSIVE DISORDER; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; PSYCHOLOGY;

ANIMALS; COGNITION; COGNITION DISORDERS; DEPRESSIVE DISORDER; FLUVOXAMINE; HUMANS; RECEPTORS, SIGMA; TREATMENT OUTCOME;

EID: 77950875429     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1106     Document Type: Review

References (65)

1. Bergeron R, Debonnel G. 1997. Effects of low and high doses of selective sigma ligands: further evidence suggesting the existence of different subtypes of sigma receptors. Psychopharmacology 129: 215-224. (Pubitemid 27085391)
2. Bremner JD. 1999. Does stress damage the brain? Biol Psychiatry 45: 797-805.
3. Bremner JD, Narayan M, Anderson ER. 2000. Hippocampal volume reduction in major depression. Am J Psychiatry 157: 115-118. (Pubitemid 30027430)
4. Campbell S, Macqueen G. 2004. The role of the hippocampus in the pathophysiology of major depression. J Psychiatry Neurosci 29: 417-426. (Pubitemid 40075713)
5. Candrian M, Farabaugh A, Pizzagalli DA, et al. 2007. Perceived stress and cognitive vulnerability mediate the effects of personality disorder comorbidity on treatment outcome in major depressive disorder: a path analysis study. Nerv Ment Dis 195: 729-737. (Pubitemid 351627637)
6. Crane C, Barnhofer T, Williams JM. 2007. Reflection, brooding, and suicidality: a preliminary study of different types of rumination in individuals with a history of major depression. Br J Clin Psychol 46: 497-504. (Pubitemid 350225904)
7. Debonnel G, de Montigny C. 1996. Modulation of NMDA and dopaminergic neurotransmissions by sigma ligands: possible implications for the treatment of psychiatric disorders. Life Sci 58: 721-734. (Pubitemid 126334914)
8. DeLuca AK, Lenze EJ, Mulsant BH, et al. 2005. Comorbid anxiety disorder in late life depression: association with memory decline over four years. Int J Geriatr Psychiatry 20: 848-854.
9. Dhikav V, Anand KS. 2007. Is hippocampal atrophy a future drug target? Med Hypotheses 68: 1300-1306.
10. Egashira N, Harada S, Okuno R, et al. 2007. Involvement of the sigma1 receptor in inhibiting activity of fluvoxamine on marble-burying behavior: comparison with paroxetine. Eur J Pharmacol 563: 149-154. (Pubitemid 46602243)
11. Elderkin-Thompson V, Boone KB, Hwang S, et al. 2004. Neurocognitive profiles in elderly patients with frontotemporal degeneration or major depressive disorder. J Int Neuropsychol Soc 10: 753-771. (Pubitemid 39264100)
12. Fava M. 2003. Symptoms of fatigue and cognitive/executive dysfunction in major depressive disorder before and after antidepressant treatment. J Clin Psychiatry 64: 30-34. (Pubitemid 37445017)
13. Fava M. 2006. Pharmacological approaches to the treatment of residual symptoms. J Psychopharmacol 20: 29-34. (Pubitemid 44605930)
14. Frodl T, Meisenzahl E, Zetzsche T, et al. 2002. Enlargement of the amygdala in patients with a first episode of major depression. Biol Psychiatry 51: 708-714. (Pubitemid 34450806)
15. Frodl TS, Koutsouleris N, Bottlender R, et al. 2008. Depression-related variation in brain morphology over 3 years: effects of stress? Arch Gen Psychiatry 65: 1156-1165.
16. Guitart X, Codony X, Monroy X. 2004. Sigma receptors: biology and therapeutic potential. Psychopharmacology 174: 301-319. (Pubitemid 39044288)
17. Hashimoto K. 2009. Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship. CNS Agents Med Chem 9: 197-204.
18. Hashimoto K, Ishiwata K., 2006. Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals. Curr Pharm Des 12: 3857-3876. (Pubitemid 44560699)
19. Hashimoto K, Fujita Y, Iyo M. 2007. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors. Neuropsychopharmacology 32: 514-521. (Pubitemid 46271046)
20. Hayashi T, Stahl SM. 2009. The sigma-1 receptor and its role in the treatment of mood disorders. Drugs Future 34: 137-146.
21. Hayashi T, Su TP. 2004. Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders. CNS Drugs 18: 269-284.
22. 2+ signalling and cell survival. Cell 131: 595-610.
23. Hayashi T, Su TP. 2008. An update on the development of drugs for neuropsychiatric disorders: focusing on the sigma 1 receptor ligand. Expert Opin Ther Targets 12: 45-58.
24. Hindmarch I. 1995. The behavioural toxicity of the selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 9: 13-17.
25. Hindmarch I, Barwell F, Alford CA. 1990. Behavioural toxicity of anti-depressants. In Antidepressants: 30 Years On. Leonard BE, Spencer P (eds). Clinical Neuroscience Publishers: London; 404-409.
26. Ishikawa M, Hashimoto K. 2010. The role of sigma-1 receptors in the pathophysiology of neuropsychiatric diseases. J Receptor Ligand Channel Res 3: 25-36.
27. 11C]SA4503. Biol Psychiatry 62: 878-883.
28. Ishima T, Fujita Y, Kohno M, et al. 2009. Improvement of phencyclidine-induced cognitive deficits in mice by subsequent subchronic administration of fluvoxamine, but not sertraline. Open Clin Chem J 2: 7-11.
29. Iyo M, Shirayama Y, Watanabe H, et al. 2008. Fluvoxamine as a sigma-1 receptor agonist improved cognitive impairments in a patient with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 32: 1072-1073.
30. John CS, Lim BB, Geyer BC, et al. 1997. 99mTc-labeled sigma-receptor-binding complex: synthesis, characterization, and specific binding to human ductal breast carcinoma T47D cells. Bioconjug Chem 8: 304-309.
31. Kamei H, Kameyama T, Nabeshima T. 1998. Effects of sigma receptor ligands on conditioned fear stress. Methods Find Exp Clin Pharmacol 20: 613-618.
32. MacQueen GM, Campbell S, McEwen BS, et al. 2003. Course of illness, hippocampal function, and hippocampal volume in major depression. Proc Natl Acad Sci USA 100: 1387-1392.
33. Maletic V, Robinson M, Oakes T, et al. 2007. Neurobiology of depression: an integrated view of key findings. Int J Clin Pract 61: 2030-2040. (Pubitemid 350077413)
34. Mamiya T, Noda Y, Noda A, et al. 2000. Effects of sigma receptor agonists on the impairment of spontaneous alternation behavior and decrease of cyclic GMP level induced by nitric oxide synthase inhibitors in mice. Neuropharmacology 39: 2391-2398. (Pubitemid 30642782)
35. Mandelli L, Serretti A, Colombo C, et al. 2006. Improvement of cognitive functioning in mood disorder patients with depressive symptomatic recovery during treatment: an exploratory analysis. Psychiatry Clin Neurosci 60: 598-604. (Pubitemid 44337482)
36. Martin WR, Eades CG, Thompson JA, et al. 1976. The effects of morphine-and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharm Exp Ther 197: 517-532.
37. Maurice T, Lockhart BP. 1997. Neuroprotective and anti-amnesic potentials of sigma receptor ligands. Prog Neuropsychopharmacol Biol Psychiatry 21: 69-102. (Pubitemid 27145413)
38. Maurice T, Phan VL, Noda Y, et al. 1999a. The attenuation of learning impairments induced after exposure to CO or trimethyltin in mice by sigma sigma receptor ligands involves both sigma1 and sigma2 sites. Br J Pharmacol 127: 335-342.
39. Maurice T, Phan VL, Urani A, et al. 1999b. Neuroactive neurosteroids as endogenous effectors for the sigma1 sigma1 receptor: pharmacological evidence and therapeutic opportunities. Jpn J Pharmacol 81: 125-155.
40. Maurice T, Urani A, Phan VL, et al. 2001. The interaction between neuroactive steroids and the sigma1 receptor function: behavioral consquences and therapeutic opportunities. Brain Res Rev 37: 116-132.
41. McEwen BS. 2003. Mood disorders and allostatic load. Biol Psychiatry 54: 200-207.
42. Mervaala E, Fohr J, Kononen M, et al. 2000. Quantitative MRI of the hippocampus and amygdala in severe depression. Psychol Med 30: 117-125.
43. Monnet FP. 2005. Sigma-1 receptor as regulator of neuronal intracellular Ca2+: clinical and therapeutic relevance. Biol Cell 97: 873-883.
44. Narita N, Hashimoto K, Tomitaka S, et al. 1996. Interactions of selective serotonin reuptake et al. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptor in rat brain. Eur J Pharmacol 307: 117-119.
45. Nishimura T, Ishima T, Iyo M, et al. 2008. Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways. PLoS ONE 3: e2558.
46. Perez A, Ashford JJ. 1990. A double-blind, randomized comparison of fluvoxamine with mianserin in depressive illness. Curr Med Res Opin 12: 234-241. (Pubitemid 20381459)
47. Phan VL, Urani A, Romieu P, et al. 2002. Strain differences in sigma1 receptor-mediated behaviours are related to neurosteroid levels. Eur J Neurosci 15: 1523-1534. (Pubitemid 35477983)
48. Porter RJ, Gallagher P, Thompson JM, et al. 2003. Neurocognitive impairment in drug-free patients with major depressive disorder. Br J Psychiatry 182: 214-220. (Pubitemid 36286734)
49. Reagan LP, Grillo CA, Piroli GG. 2008. The As and Ds of stress: metabolic, morphological and behavioral consequences. Eur J Pharmacol 585: 64-75.
50. Ridout F, Meadows R, Johnsen S, et al. 2003. A placebo controlled investigation into the effects of paroxetine and mirtazapine on measures related to car driving performance. Hum Psychopharmacol 18: 261-269. (Pubitemid 36722311)
51. Roman FJ, Pascaud X, Martin B, et al. 1990. JO 1784, a potent and selective ligand for rat and mouse brain sigma-sites. J Pharm Pharmacol 42: 439-440. (Pubitemid 20313697)
52. Sapolsky RM. 2001. Depression, antidepressants, and the shrinking hippocampus. Proc Natl Acad Sci USA 98: 12320-12322.
53. Schmitt JA, Kruizinga MJ, Riedel WJ. 2001. Non-serotonergic pharmacological profiles and associated cognitive effects of serotonin reuptake inhibitors. J Psychopharmacol 15: 173-179.
54. Senda T, Matsuno K, Okamoto K, et al. 1996. Ameliorating effect of SA4503, a novel sigma1 receptor agonist, on memory impairments induced by cholinergic dysfunction in rats. Eur J Pharmacol 315: 1-10. (Pubitemid 26390943)
55. Sheline YI, Sanghavi M, Mintun MA, et al. 1999. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci 19: 5034-5043. (Pubitemid 29270138)
56. Sherwood CC, Subiaul F, Zawidzki TW. 2008. A natural history of the human mind: tracing evolutionary changes in brain and cognition. J Anat 212: 426-454. (Pubitemid 352024466)
57. Silva H, Larach V. 2000. Treatment and recovery rate in depression: a critical analysis. World J Biol Psychiatry 1: 119-123.
58. Spring B, Gelenberg AJ, Garvin R, et al. 1992. Amitriptyline, clovoxamine and cognitive function: a placebo-controlled comparison in depressed outpatients. Psychopharmacology 108: 327-332.
59. Stahl SM. 2005. Antidepressant treatment of psychotic major depression: potential role of the sigma receptor. CNS Spectr 10: 319-323.
60. Stahl SM. 2008. The sigma enigma: can sigma receptors provide a novel target for disorders of mood and cognition? J Clin Psychiatry 69: 1673-1674.
61. Steffens DC, Byrum CE, McQuoid DR, et al. 2000. Hippocampal volume in geriatric depression. Biol Psychiatry 48: 301-309.
62. Stein RA, Strickland TL. 1998. A review of the neuropsychological effects of commonly used prescription medications. Arch Clin Neuropsychol 13: 259-284.
63. Su TP, Hayashi T. 2003. Understanding the molecular mechanism of sigma-1 receptors: towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal transduction. Curr Med Chem 10: 2073-2080. (Pubitemid 37139064)
64. Takebayashi M, Hayashi T, Su TP. 2002. Nerve growth factor-induced neurite sprouting in PC12 cells involves sigma1-receptors: implications for antidepressants. J Pharmacol Exp Ther 303: 1227-1237. (Pubitemid 35424409)
65. Thapa PB, Gideon P, Cost TW, et al. 1998. Antidepressants and the risk of falls among nursing home residents. N Engl J Med 339: 875-882. (Pubitemid 28446845)